The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

City of Hope and TGen research reveals potential cause of aggressive leukemia

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Research from City of Hope and the Translational Genomics Research Institute, part of City of Hope, suggests that loss of a specific RNA molecule, miR-142, may lead to more aggressive forms of chronic myeloid leukemia. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment

As the chief scientific officer of the Leukemia & Lymphoma Society for the past eleven years, it has been a privilege to lead a group of scientists that has doled out more than $600 million for cutting-edge hematologic oncology research. These dollars went to more than 1,000 research projects through initiatives like our biomedical research grant programs and LLS’s venture philanthropy, the Therapy Acceleration Program (TAP). 
By Lee Greenberger
Sponsored

At City of Hope, our path to innovation includes surgical simulations in space, diverse genomics data—and more

Earlier this week at City of Hope, we celebrated World Cancer Day by announcing ambitious solutions to tackle some of the most pressing challenges in cancer care. This includes groundbreaking advancements in microbiome research aimed at improving cancer survival, increased emphasis on cancers that disproportionately affect women and people of color, and enhanced access to advanced cancer treatment.
By City of Hope
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account